Funding profile · At-home hormone diagnostics

Inito

Eleven years of angel and family office money, then two institutional rounds inside twenty five months. No Regulation D paper trail exists, because the capital never went into a US issuer.

Data as of September 23, 2026. Company-reported figures are labeled.

Rounds at a glance

What the filings show

There are none in the United States. An EDGAR company search for Inito returns no matching companies, and a full text search for the exact phrase returns zero documents. No Form D, no Form D amendment, no investment vehicle formed around the company.

That is the expected result rather than a red flag. Regulation D governs securities sold into the US market. Inito raised into Indian entities from mostly Indian and Asian investors, and the 2025 lead, Bertelsmann India Investments, invests from India. Filings for this company sit with the Ministry of Corporate Affairs, not the SEC.

The only US federal records naming the company are regulatory, not financial: an establishment registration and device listing for Inito Health Tech Private Limited, registration 3038290392, listed May 7, 2025, under product code NGE, plus four Indian contract manufacturers that have listed Inito strips or readers since October 2020.

Reading the filings

1. The totals do not reconcile.TechCrunch put pre-Series B funding at $15M in November 2023, made of $9M early money plus the $6M Series A. Add the $29M Series B and the arithmetic gives $44M. The company and four outlets say $45M. DC Advisory, which ran the sale side, says $48M. The $3M gap between the adviser and the issuer is unexplained.
2. Nine years to the first institutional cheque.First money in late 2014, first named venture lead in November 2023. Rai told Moneycontrol in 2020 that he had reached out to angel investors who have patient capital, and that he was not looking for more equity rounds. That is a long bootstrap for a hardware and assay company.
3. Growth decelerated into the round.VCCEdge figures put FY24 revenue at ₹53.17 crore, more than double the prior year, and FY25 at ₹67.6 crore, up 27 percent. The Series B closed on that slowing curve, and the pitch it closed on was a platform story about AI engineered antibodies rather than a fertility growth story.
4. There is no regulatory moat.No 510(k), no PMA, no De Novo. The device is marketed under a Class I exemption in product code NGE, which any competent competitor can also register into. The adviser describes the moats as IP and technology, and the company claims more than 20 patents. None of that is a barrier a regulator enforces.
5. Manufacturing is contracted and it moves.Four different Indian contract manufacturers have appeared on FDA listings for Inito products between October 2020 and February 2026. Capital efficiency comes partly from not owning the line, and so does supplier concentration risk.

Commercial signals

What to watch

• Whether the $45M and $48M totals are ever reconciled in a later disclosure.
• FY26 revenue. A second year in the twenties would make the platform pivot the whole story.
• Whether any new test needs a 510(k). A cleared assay would change the moat argument and the cost base at once.
• Whether a US issuer is ever formed. A Form D would be the first sign of a US flip ahead of a later round.
• Granted patents behind the claim of more than 20.

The Inito story on Healthcare DiscoveryHealthcare Discovery

Related companies

• Orange Health Labs: Shared investor: Bertelsmann India Investments. An Indian diagnostics company that draws blood at home in under an hour and returns reports in six
• GEn1E Lifesciences: Shared investor: M Angels. A Palo Alto company built on a different way to hit p38 alpha kinase, a target big pharma abandoned twenty years ago
• Modern Fertility: Also in Consumer Health and Wellness. A finger prick hormone panel sold to women who were not trying to conceive
• Lilia: Also in Consumer Health and Wellness. A Y Combinator backed service that bundled discounted egg freezing cycles with a single point of contact for scheduling, meds, and clinic referrals

Sources

1. Public recordEDGAR company and full text search returning no Inito filingsSEC · Sep 23, 2026
2. Public recordFDA registration and listing, Inito Health Tech Private LimitedopenFDA · listed May 7, 2025
3. Public recordFDA product classification, code NGE, 510(k) exemptFDA · Sep 23, 2026
4. Public recordMAUDE adverse event reports, Inito devicesopenFDA · 2022 to 2025
5. IndependentInito bags $29 mn in Series B, with VCCEdge revenue and round historyVCCircle · Dec 11, 2025
6. IndependentFertility startup Inito wants to use AI-designed antibodiesTechCrunch · Dec 10, 2025
7. IndependentInito raises $6M, with total funding to dateTechCrunch · Nov 15, 2023
8. IndependentInito raises $29M to expand AI-powered at-home diagnosticsYourStory · Dec 11, 2025
9. IndependentGiving DIY diagnostics a boost, the Inito wayMoneycontrol · Nov 3, 2020
10. AdviserDC Advisory advises Inito on its Series B fundraiseDC Advisory · Dec 2025
11. CompanyInito Series B announcement and product pagesInito · Dec 11, 2025

Compiled from SEC, FDA and other public records and published reports as of September 23, 2026. No Form D or other Regulation D notice exists for this company; round figures are drawn from company statements and press reports and are not audited. Healthcare Venture Capital Fund holds no position in Inito. This page is not an offer to sell or a recommendation to buy any security.